title: [Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation].
abstract: Patients (n=187) with symptomatic persistent atrial fibrillation at the background of ischemic heart disease after restoration of sinus rhythm were randomized for treatment with sotalol 80 - 160 mg/day (n=48), or with combinations of sotalol with perindopril 4 - 8 mg/day (n=48), rosuvastatin 5 - 20 mg/day (n=45), or omega-3 polyunsaturated fatty acids containing preparation 1 g/day (n=45). After 12 months sinus rhythm was maintained in 77.6, 93.8 (p < 0.05), 86.7, and 84.4% of cases, respectively, after conduction on the average 7.9 +/- 1.6, 4.3 +/- 1.0 (p < 0.05), 6.5 +/- 1.7, 7.2 +/- 1.8 pharmacological cardioversions per 1 patient in groups of comparison, respectively. Plasma level of high sensitivity C-reactive protein was lowered by all variants of combination therapy, while anterior-posterior left atrial diameter - only under the influence of perindopril. Antiinflammatory effect of nonarrhythmic drugs is able to play substantial role in prevention of atrial fibrillation, however antiremodeling and hemodynamic effects of therapy probably possess no less important significance.
authors.forename: S G
authors.initials: SG
authors.lastname: Kanorskiĭ
authors.forename: V V
authors.initials: VV
authors.lastname: Bodrikova
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Kanorskaia
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D055502:Secondary Prevention; D013015:Sotalol / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D015525:Fatty Acids, Omega-3; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D013015:Sotalol; D020913:Perindopril